(KOD) – Analyst Ratings
-
Goldman Sachs Reinstates Kodiak Sciences Inc. (KOD) at Sell, 'Cautious on the tarcocimab reboot'
-
CapitalOne Upgrades Kodiak Sciences Inc. (KOD) to Overweight
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to KOD Stock Lookup